Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of sickle cell disease.Open Access

Over 4 Years of Safety and Efficacy with Voxelotor in Patients with Sickle Cell Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

RBR. Clark BrownEmory UniversityMark M. DavisMark M. DavisNew Mexico State UniversityMAMaureen AchebeBeth Israel Deaconess Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Brown et al. (2024) studied this question.

synapsesocial.com/papers/68e67069b6db6435875fb0d4https://doi.org/10.1093/jscdis/yoae002.008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Voxelotor for Sickle Cell Disease: Initial Report from the Real-world PROSPECT Study2024 · 1 citations
  2. 2A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease2019 · 116 citations
  3. 3Safety and efficacy of voxelotor in adult patients with sickle cell disease2026
  4. 4Real-world experience of voxelotor treatment in patients with sickle cell disease2025
  5. 5Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries2026 · 4 citations